VRCA — Verrica Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $60.64m
- $50.84m
- $35.58m
Verrica Pharma reports wider-than-expected Q2 adj loss per share
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Verrica Pharmaceuticals Q1 revenue rises on YCANTH demand
Brief: Verrica Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Data
Brief: Verrica Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract Highlighting Potential Abscopal Effect Of VP-315 For The Treatment Of Basal Cell Carcinoma At The Upcoming 2026 Society For Investigative Dermatology Annual Meeting
Verrica Pharmaceuticals Q4 revenue jumps on stronger YCANTH demand
Brief: Verrica Pharmaceuticals Appoints Chris Chapman As Chief Commercial Officer
Brief: Verrica Pharmaceuticals Announces Launch Of Ycanth® For The Treatment Of Molluscum Contagiosum In Japan
Brief: Verrica Pharmaceuticals Announces First Patient Dosed In Phase 3 Program
Brief: Verrica Pharmaceuticals Enters Securities Purchase Agreement With Institutional Investors
Brief: Verrica Pharmaceuticals announces private placement financing of $50 million
Verrica Pharmaceuticals Q3 net loss narrows
Brief: Verrica Pharmaceuticals Receives Positive Feedback From The European Medicines Agency (EMA) Supporting A Clear Regulatory Path Forward To File For Approval Of Ycanth® In The European Union
Verrica Pharma climbs after EU nod clears path for skin drug filing
U.S. STOCKS ON THE MOVE-BILL Holdings, Jackson Financial, Wills Towers Watson
U.S. STOCKS ON THE MOVE-Gold miners, Perpetua Resources, KalVista Pharmaceuticals
Verrica climbs after Japan's nod for skin infection drug
Brief: Verrica, Torii Win Japan Approval For YCANTH To Treat Molluscum Contagiosum
U.S. RESEARCH ROUNDUP-Apollo, Blackstone, Nvidia